Eli Lilly and Company’s Ebglyss (lebrikizumab) has won a positive recommendation from Canada’s Drug Agency (CDA-AMC) for reimbursement with conditions, clearing the path for public coverage of the biologic eczema treatment across the country. The recommendation, announced on July 8, 2026, marks a major milestone for the IL-13 inhibitor after its initial Health Canada authorization on June 24, 2024.
The pan-Canadian Pharmaceutical Alliance (pCPA) has reached a letter of intent with Lilly Canada following the CDA-AMC recommendation, enabling public drug plan reimbursement in all provinces and territories. The approval applies to adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Ebglyss demonstrated strong efficacy in clinical trials. In the ADvocate 1 monotherapy study, 59% of patients achieved EASI-75 (a 75% improvement in skin lesion severity and extent) and 43% achieved IGA 0/1 (completely clear or almost-clear skin) at week 16. The drug also delivered meaningful improvements in sleep loss and quality of life measures by week 16, according to data cited in the approval announcement.
Long-term durability has been a key strength in supporting the recommendation. Lilly released data in March 2026 showing that Ebglyss delivered durable skin clearance and relief from persistent itch for up to four years in an open-label extension study. A separate long-term extension study (ADjoin) confirmed that skin and itch results were maintained over two years of continuous lebrikizumab treatment.
Atopic dermatitis, a chronic inflammatory skin condition, carries a significant burden for patients and families. The condition is characterized by intense itching, dry red skin, and unpredictable flares that can disrupt sleep, affect mental health, and reduce productivity at work and school. Access to additional biologic treatment options addresses an unmet clinical need in Canada, where patient outcomes have been limited by the availability of fewer systemic therapies compared to other markets.
Lebrikizumab works by selectively targeting interleukin-13 (IL-13), a key inflammatory pathway in atopic dermatitis. This mechanism differs from Dupixent (dupilumab), the market-leading biologic, which targets both IL-4 and IL-13 pathways. Clinical evidence suggests lebrikizumab has comparable efficacy to dupilumab in achieving skin clearance and itch relief, offering physicians and patients another option for individualized treatment selection.
Ebglyss is administered as a subcutaneous injection on an every-4-week maintenance schedule after an initial induction phase. The FDA also approved an every-8-week maintenance regimen in June 2026, giving patients flexibility in dosing frequency once they achieve adequate clinical response. This dosing convenience has been highlighted as a competitive advantage in the crowded biologic eczema market.
Sources
- BioSpace — July 8, 2026 press release on Lilly Canada’s CDA-AMC recommendation and pCPA letter of intent for Ebglyss; clinical trial efficacy data from ADvocate 1, ADhere, and long-term extension studies.
- Dermatology Times — June 25, 2024 report on Health Canada’s authorization of lebrikizumab for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older.
- PR Newswire — June 9, 2026 FDA approval announcement for every-8-week maintenance dosing of Ebglyss; confirmation that Ebglyss was approved in Canada in 2024.
- Canadian Journal of Health Technologies — June 26, 2026 review demonstrating that Ebglyss shows acceptable clinical value versus dupilumab for atopic dermatitis treatment.
- FirstWord PHARMA — September 25, 2025 analysis of Ebglyss as a first-line biologic therapy in Canada; confirmation of June 24, 2024 Health Canada authorization date and clinical trial data from ADvocate 1, ADvocate 2, and ADhere studies.
